Atai Life Sciences N.V. is a biopharmaceutical company focused on developing innovative therapies for mental health conditions
The company leverages the potential of psychedelics and other novel compounds to address various psychiatric disorders, aiming to create safer and more effective treatment options. Through a unique platform, Atai collaborates with several research biotechnology companies, fostering an environment that promotes scientific discovery, clinical innovation, and the advancement of transformative therapies for individuals suffering from mental health challenges.
If you are considering using psychedelics in a non-clinical setting, you might want to hold off for a while. A recently published study has found that individuals who have bad psychedelic trips have a much higher risk of dying within 5 years.
- The eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial is evaluating the efficacy and safety of a single dose of BPL-003 (mebufotenin benzoate) in patients with treatment-resistant depression
NEW YORK and BERLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team is scheduled to participate in the TD Cowen 45th Annual Health Care Conference in Boston, MA from March 3-5, 2025. Details of the company’s participation:
NEW YORK and BERLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced that, on February 14, 2025, the closing of its public offering of 26,190,477 common shares occurred. Additionally, on February 17, 2025, the underwriter exercised its option in full to purchase an additional 3,928,571 common shares at the public offering price of $2.10 per share, and the closing of the underwriter’s option to purchase 3,928,571 additional common shares occurred on February 19, 2025. The aggregate gross proceeds from the offering, including the gross proceeds from the exercise of the underwriter’s option to purchase additional shares, were approximately $63.25 million, before deducting underwriting discounts and commissions and other offering expenses payable by atai.
With the existing treatments for mental health issues like PTSD, treatment-resistant depression and suicidal thoughts having limited, if any, beneficial effect, U.S. veterans have decided to take matters into their own hands and are helping one another to explore DIY approaches to using psychedelics to find relief from their symptoms.
Kennedy has previously advocated for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca.
NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the pricing of a registered underwritten offering of 26,190,477 common shares, at a price of $2.10 per share. atai has granted the underwriter a 30-day option to purchase up to an additional 3,928,571 common shares. All common shares to be sold in the offering will be sold by atai.
NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the commencement of a proposed registered underwritten offering of $55,000,000 of its common shares. atai expects to grant the underwriter a 30-day option to purchase up to an additional $8,250,000 of common shares. All common shares to be sold in the offering will be sold by atai.
- A single dose of BPL-003, combined with relapse prevention therapy, produced meaningful and sustained reductions in alcohol use, with 50% of patients maintaining complete abstinence out to three months
- Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief Medical Officer- Glenn Short, Ph.D. promoted to Chief Scientific Officer- Gerd Kochendoerfer, Ph.D. joins as Chief Operating Officer
- The United States Food and Drug Administration cleared the investigational new drug application for VLS-01 (buccal film DMT); atai expects to initiate a Phase 2 study in treatment-resistant depression patients around YE’24
NEW YORK and BERLIN, Oct. 15, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that Srinivas Rao, M.D., Ph.D., the Company’s Co-founder and Co-CEO, is scheduled to participate in the 2024 Maxim Healthcare Virtual Summit taking place from October 15 – 17, 2024. Details of the company’s participation:
While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are having growing pains.
The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a Portfolio of the 4 largest such companies.
The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development.
